<SEC-DOCUMENT>0001104659-25-123133.txt : 20251219
<SEC-HEADER>0001104659-25-123133.hdr.sgml : 20251219
<ACCEPTANCE-DATETIME>20251219161115
ACCESSION NUMBER:		0001104659-25-123133
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20251219
FILED AS OF DATE:		20251219
DATE AS OF CHANGE:		20251219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nyxoah SA
		CENTRAL INDEX KEY:			0001857190
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			C9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40552
		FILM NUMBER:		251587646

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		RUE EDOUARD BELIN 12
		CITY:			MONT-SAINT-GUIBERT
		PROVINCE COUNTRY:   	C9
		ZIP:			1435
		BUSINESS PHONE:		3210222355

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		RUE EDOUARD BELIN 12
		CITY:			MONT-SAINT-GUIBERT
		PROVINCE COUNTRY:   	C9
		ZIP:			1435
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2533876d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of December 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>001-40552</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NYXOAH SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rue
Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT> Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note</B></FONT>:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report
to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note</B></FONT>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on
which the registrant&rsquo;s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nyxoah SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Notes
Offering </U></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, on November 13, 2025,
the Company entered into a Subscription Agreement (the &ldquo;Notes Subscription Agreement&rdquo;) with a certain institutional investor
(the &ldquo;Notes Investor&rdquo;), pursuant to which the Company agreed to sell, and the Notes Investor agreed to purchase, up to &euro;45.0
million in aggregate principal amount of amortizing senior unsecured convertible notes at an 8.0% original issue discount (the &ldquo;Notes
Offering&rdquo;), consisting of an initial tranche of &euro;22.5 million amortizing senior unsecured convertible notes (the &ldquo;First
Tranche Notes&rdquo;) and a second tranche of &euro;22.5 million amortizing senior unsecured convertible notes (the &ldquo;Second Tranche
Notes,&rdquo; and together with the First Tranche Notes, the &ldquo;Notes&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 16, 2025, the Company entered into
an Amended and Restated Subscription Agreement (the &ldquo;Amended and Restated Notes Subscription Agreement&rdquo;) with the Notes Investor,
pursuant to which the Company agreed to, among other things, pay to the Notes Investor, in lieu of an original issue discount, a subscription
fee equal to 8.0% of the principal amount of the First Tranche Notes and the Second Tranche Notes, as applicable, at issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the execution of the Amended
and Restated Notes Subscription Agreement, on December 18, 2025, the Company issued the First Tranche Notes to the Notes Investor, and
paid a subscription fee to the Notes Investor of approximately &euro;1.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, the issuance of the
Second Tranche Notes is subject to additional customary closing conditions and will take place upon satisfaction of such closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the successful issuance of the Second
Tranche Notes, the gross amount of proceeds to us from the Notes Offering will be approximately &euro;41.4 million. The Company expects
to use the proceeds from the Notes Offering for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The above is intended to provide a summary of the terms of the Amended
and Restated Notes Subscription Agreement and the Notes. This summary is qualified in its entirety by reference to the full text of the
Amended and Restated Notes Subscription Agreement and the Notes, which will be attached as exhibits to a future filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Report on Form 6-K shall not constitute
an offer to sell or the solicitation to buy nor shall there be any sale of the Company&rsquo;s securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes, and any ordinary shares issuable upon
the conversion or settlement thereof, including in connection with the amortization of such Notes, are not being registered under the
Securities Act of 1933, as amended. The ordinary shares are being offered to non-U.S. Persons (as such term is defined under Rule 902
of Regulation S) in a transaction outside the United States pursuant to Regulation S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
information included under the heading &ldquo;</I></FONT>Note Offering<I>&rdquo; of this report on Form 6-K shall be deemed to be incorporated
by reference into the registration statements on Form S-8 (Registration Numbers </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465925026217/tm259582-1_f3.htm" STYLE="-sec-extract: exhibit"><I>333-285960</I></A><I>,
</I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465921141913/tm2133261d1_s8.htm" STYLE="-sec-extract: exhibit"><I>333-261233</I></A> <I>and </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465923006563/tm234202d1_s8.htm" STYLE="-sec-extract: exhibit"><I>333-269410</I></A><I>)
and Form F-3 (Registration Numbers </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465925026217/tm259582-1_f3.htm" STYLE="-sec-extract: exhibit"><I>333-285982</I></A>
<I>and </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465922129515/tm2232874-1_f3.htm" STYLE="-sec-extract: exhibit"><I>333-268955</I></A><I>)
of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on
which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Press Releases</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2025, the Company issued a press
release announcing the commercial launch of its Genio system in the Netherlands. A copy of the Company&rsquo;s press release is attached
hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 19, 2025, the Company issued a press
release announcing the issuance of the First Tranche Notes and providing an update regarding the Company&rsquo;s cash runway. A copy
of the Company&rsquo;s press release is attached hereto as Exhibit 99.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The information in the attached Exhibit 99.1
is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise
set forth herein or as shall be expressly set forth by specific reference in such a filing.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
information under the headings &ldquo;</I></FONT>Closing of the first tranche of the convertible bonds&rsquo; issuance<I>&rdquo; and
&ldquo;</I>Second tranche convertible bonds<I>&rdquo; in the attached Exhibit 99.2 shall be deemed to be incorporated by reference into
the registration statements on Form S-8 (Registration Numbers </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465925026217/tm259582-1_f3.htm" STYLE="-sec-extract: exhibit"><I>333-285960</I></A><I>,
</I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465921141913/tm2133261d1_s8.htm" STYLE="-sec-extract: exhibit"><I>333-261233</I></A> <I>and </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465923006563/tm234202d1_s8.htm" STYLE="-sec-extract: exhibit"><I>333-269410</I></A><I>)
and Form F-3 (Registration Numbers </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465925026217/tm259582-1_f3.htm" STYLE="-sec-extract: exhibit"><I>333-285982</I></A>
<I>and </I><A HREF="https://www.sec.gov/Archives/edgar/data/1857190/000110465922129515/tm2232874-1_f3.htm" STYLE="-sec-extract: exhibit"><I>333-268955</I></A><I>)
of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on
which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Exhibits</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt"><A HREF="tm2533876d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="width: 90%; font-size: 10pt"><A HREF="tm2533876d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release,
    dated December 17, 2025.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="tm2533876d1_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2533876d1_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated December
    19, 2025.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYXOAH SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 19, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Landry</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Landry</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2533876d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2533876d1_ex99-1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Nyxoah Announces Commercial Launch of Genio&reg; Breakthrough
Therapy in the Netherlands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">December 17, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Nyxoah Announces Commercial Launch of Genio&reg; Breakthrough
Therapy in the Netherlands</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>First Genio implants successfully performed at OLVG West
and Zuyderland hospitals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Mont-Saint-Guibert, Belgium &ndash; December 17, 2025,
7:05am CET / 1:05am ET &ndash; Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) </B>(&ldquo;Nyxoah&rdquo; or the &ldquo;Company&rdquo;), a
medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation,
today announced the commercial launch of its Genio&reg; system in the Netherlands, marked by the first successful Genio implants performed
at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Commenting on the introduction of Genio
in Amsterdam, Dr. Peter van Maanen, ENT surgeon at OLVG West, stated: &ldquo;Dr. Mayke Hentschel, our sleep department and I are pleased
to offer our patients an additional treatment option for OSA when CPAP is not tolerated. With Genio, patients finally have a real choice.
The system stimulates both branches of the nerve, has no internal battery, is full body 1.5 and 3T MRI-compatible, and can be easily
upgraded via the external activation chip. These features make it a promising long-term solution for both patients and healthcare providers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">At Zuyderland Hospital, Dr. Jos Straetmans,
ENT surgeon in Heerlen and Sittard, added: &ldquo;Introducing the Genio bilateral neurostimulation system expands our ability to tailor
therapy to the needs of each individual patient. Its advantages: no implanted battery, and reliable performance in the supine position
make it a valuable addition to our treatment arsenal. We are excited to bring this innovative, European developed technology to patients
in our community.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;The commercial launch of Genio
in the Netherlands marks another important step in our European rollout and reflects growing adoption of our bilateral, externally powered
Genio therapy,&rdquo; commented Olivier Taelman, Nyxoah's Chief Executive Officer. &ldquo;We are proud to partner with leading Dutch
centers to bring Genio to patients seeking an effective and patient-centric alternative to CPAP. As we continue to expand our commercial
footprint, these early implants further validate Genio&rsquo;s role as a long-term solution for OSA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>About Nyxoah</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Nyxoah is a medical technology company
focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah&rsquo;s lead solution is the Genio system,
a patient-centric, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world&rsquo;s most common sleep disordered
breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision
that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Following the successful completion
of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels
in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval
for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors&rsquo;
therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA
for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">For more information, please visit <U>http://www.nyxoah.com/.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Caution &ndash; CE marked since 2019. FDA approved in August
2025 as prescription-only device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Forward-looking statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain statements,
beliefs and opinions in this press release are forward-looking, which reflect the Company&rsquo;s or, as appropriate, the Company
directors&rsquo; or managements&rsquo; current expectations regarding the Genio system; the potential advantages of the Genio
system; Nyxoah&rsquo;s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and
entrance to the U.S. market; and the Company' results of operations, financial condition, liquidity, performance, prospects, growth
and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors
that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements.
These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events
described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the
&ldquo;Risk Factors&rdquo; section of the Company&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2024, filed
with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on March 20, 2025 and subsequent reports that the Company files with
the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in
this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a
representation that such trends or activities will continue in the future. In addition, even if actual results or developments are
consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative
of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such
forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or
revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do
so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Nyxoah</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">John Landry, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>
IR@nyxoah.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">R&eacute;mi Renard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Chief Investor Relations &amp; Corporate Communication Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>
IR@nyxoah.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Attachment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> &nbsp;<U>
ENGLISH_Nyxoah Announces Commercial Launch of Genio Breakthrough Therapy in the Netherlands</U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm2533876d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2533876d1_ex99-2img01.jpg" ALT=""></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nyxoah Announces Issuance of First
Tranche of Convertible Bonds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mont-Saint-Guibert, Belgium &ndash; December
19, 2025, 10:05pm CET / 4:05pm ET &ndash; Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)</B> (&ldquo;<B>Nyxoah</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;),
a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA) through neuromodulation, today announced the issuance of the first tranche of the convertible bond financing entered into with an
entity managed by Heights Capital Management (&ldquo;<B>HCM</B>&rdquo;) of up to &euro;45 million, as previously announced by the Company
on November 13, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Closing of the first tranche of the convertible
bonds&rsquo; issuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 18, 2025, the Company issued the first
tranche of convertible bonds for a nominal amount of &euro;22.5 million under the subscription agreement entered into with HCM on November&nbsp;13,
2025, as amended and restated on December 16, 2025. The first tranche consisted of the issuance of 225 convertible bonds (the &ldquo;<B>First
Tranche Bonds</B>&rdquo;) with a nominal amount of &euro;100,000 each, which were fully subscribed to and paid-up by HCM. Pursuant to
the subscription agreement, the Company has paid a subscription fee to HCM equal to 8.0 per cent of the principal amount of the First
Tranche Bonds (i.e.,&nbsp;&euro;1.8&nbsp;million), which has been satisfied by set-off against the respective portion of the subscription
price of the First Tranche Bonds due by HCM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The First Tranche Bonds carry an interest rate
of 6.5 per cent per annum and have a three-year maturity from issuance with quarterly amortization payments (each a &ldquo;<B>Scheduled
Amortisation Payment Date</B>&rdquo;) of principal (equal to an amount of &euro;8.500 per First Tranche Bond, except for the final amortization
payment which will be equal to &euro;6.500 per First Tranche Bond, each an &ldquo;<B>Amortised Payment Amount</B>&rdquo;) and interest.&nbsp;The
first Scheduled Amortisation Payment Date will be on February 18, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the scheduled amortisation payments,
HCM (or any future holders of the majority of the First Tranche Bonds) may, at any time between two Scheduled Amortisation Payment Dates
(a &ldquo;<B>Regular Amortisation Period</B>&rdquo;), exercise its right to bring forward the payment of up to two Amortised Payment Amounts
to a date specified in a notice sent to the Company which shall not be earlier than three business days following the date on which the
relevant notice is given. Additionally, HCM (or any future holders of the majority of the First Tranche Bonds) will also have the right
to defer the payment of any upcoming Amortised Payment Amount to any subsequent Scheduled Amortisation Payment Date specified in the notice
sent to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HCM may elect to convert the outstanding principal
amount under the First Tranche Bonds or any Amortized Payment Amount at any time during the term of the bonds. The initial conversion
price for the First Tranche Bonds, which can be modified on a downward basis, shall be equal to &euro;5.00, which represents 125 per cent
of the placement price of the shares that have been issued pursuant to the previously announced private placement and registered direct
offering (the &ldquo;<B>Capital Increases</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2533876d1_ex99-2img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each payment of the Amortised Payment Amounts
shall in principle be done in cash at an amount equal to 103 per cent of the principal amount of such Amortised Payment Amount. However,
the Company may elect to satisfy its obligation to repay the relevant Amortised Payment Amount by issuing new ordinary shares in the Company
to HCM (the &ldquo;<B>Share Settlement Option</B>&rdquo;). In case the Company exercises its Share Settlement Option, the issue price
for the newly to be issued ordinary shares will be the lower of (a) the conversion price in effect at the time, and (b) 90% of the lower
of (i) the VWAP of an ordinary share on the relevant Scheduled Amortisation Payment Date, and (ii) the lowest of the VWAPs of an ordinary
share on each of the five consecutive dealing days ending on (and including) such Scheduled Amortisation Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More information on the First Tranche Bonds is
available in the special report of the board of directors of the Company drawn up in accordance with articles 7:180, 7:191 and 7:193 of
the Belgian Code on companies and associations located at https://investors.nyxoah.com/financials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Second tranche convertible bonds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the subscription agreement, the Company
has the option to issue a second tranche of convertible bonds (the &ldquo;<B>Second Tranche Bonds</B>&rdquo;) to HCM for an aggregate
principal amount of up to &euro;22.5 million if so requested by the Company in the period between July 18, 2026 and August 18, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and HCM can agree in writing to a
lesser aggregate principal amount than &euro;22.5 million for the Second Tranche Bonds issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The obligation for HCM to subscribe to the Second
Tranche Bonds on the closing date for the Second Tranche Bonds (the &ldquo;<B>Second Tranche Closing Date</B>&rdquo;) shall be subject
to certain customary conditions precedent being satisfied (or waived by HCM) prior to or on the Second Tranche Closing Date. More specifically,
it is, among others, required that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the arithmetic mean (rounded to the nearest whole multiple of U.S.$1.00 (with U.S.$0.50 being rounded
upwards)) of the daily traded values of the ordinary shares of the Company on each dealing day comprised in the period of sixty qualifying
stock exchange days ending on the qualifying stock exchange date immediately preceding the date of the Company&rsquo;s request to issue
the Second Tranche Bonds is greater than U.S.$1 million (or its equivalent in any other currency); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company has a last market capitalisation immediately preceding the Second Tranche Closing Date, and
an average market capitalisation on each of the 30 consecutive dealing days ending on (and including) the dealing day immediately preceding
the Second Tranche Closing Date that are each greater than &euro;240,000,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2533876d1_ex99-2img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As of December 16, 2025,
the conditions precedent relating to the daily traded values, the last market capitalisation and the average market capitalisation
were not met. More precisely, as of December 16, 2025, the arithmetic mean of the daily traded values amounted to U.S.$ 772,176, the
last market capitalisation amounted to &euro;177,053,883 and the 30-day average market capitalisation amounted to
&euro;175,959,735.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Second Tranche Bonds shall,
to the extent applicable, be issued on substantially the same terms as the First Tranche Bonds. The initial conversion price of the Second
Tranche Bonds shall be equal to the lowest of the five VWAPs of the ordinary shares of the Company on Euronext Brussels on each of the
five dealing days ending on the Second Tranche Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash runway</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of the First Tranche Bonds and closing
of the Capital Increases, together with the second tranche under the Company&rsquo;s existing credit facility with the European Investment
Bank (for which the possibility to draw depends on a revenue milestone that the Company expects to meet in the first half of 2026), will
extend the Company&rsquo;s cash runway into the third quarter of 2026. If, in addition to the foregoing, the Second Tranche Bonds are
issued, the Company&rsquo;s cash runway will be extended by two (2) quarters, into the first quarter of 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds from the First Tranche Bonds
together with the net proceeds of the Capital Increases will be used (i) to support commercialization activities in the United States
and advance the commercialization of the Genio system in the Company&rsquo;s initial target markets outside the United States; (ii) to
continue gathering clinical data and to support physician-initiated clinical research projects related to OSA patient treatments; (iii)
to further finance research and development activities related to Genio system upgrades, re-designing the Company&rsquo;s products for
manufacturability and cost reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration
opportunities in the field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited
to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such
offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Nyxoah</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nyxoah is a medical technology company focused
on the development and commercialization of innovative solutions to treat OSA. Nyxoah&rsquo;s lead solution is the Genio system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world&rsquo;s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should
enjoy restful nights and feel enabled to live their life to its fullest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2533876d1_ex99-2img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the successful completion of the BLAST
OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September
2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion
of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors&rsquo; therapy.
Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset
of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Caution &ndash; CE marked since 2019. FDA approved
in August 2025 as prescription-only device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY
OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION
ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE, OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE, ANY SECURITIES. THE
DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER, SUBSCRIPTION, SALE AND PURCHASE OF SECURITIES DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN
JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements, beliefs and opinions in
this press release are forward-looking, which reflect the Company&rsquo;s or, as appropriate, the Company directors&rsquo; or
managements&rsquo; current expectations regarding the convertible bond financing; the Genio system; the potential advantages of the
Genio system; Nyxoah&rsquo;s goals with respect to the potential use of the Genio system; the Company's commercialization strategy
and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects,
growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other
factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the
plans and events described herein. These risks and uncertainties include, but are not limited to, the satisfaction of the closing
conditions required for the Second Tranche Bonds and the corresponding closing, the use of net proceeds from the First Tranche
Bonds, the expected sufficiency of the Company&rsquo;s cash resources and runway, which may not be accurate resulting in the need
for additional financing sooner than anticipated, the risks and uncertainties set forth in the &ldquo;Risk Factors&rdquo; section of
the Company&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025 and
subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or results to differ significantly from any anticipated
development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of
future performance and should not be taken as a representation that such trends or activities will continue in the future. In
addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release,
those results or developments may not be indicative of results or developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking
statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak only as of the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nyxoah</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Landry, CFO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>IR@nyxoah.com</U></P>



<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2533876d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533876d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !. .@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_4R(!DG]
M"?Y"D66-NC$]?X6'3KU _P#K]JB\Z(YWLJK@\$C"\\Y(Z=#G]:7<A4F-@!G&
M0K<Y ^8<?,O(^890=VX(!:337))2VYFFJ=^K[M=K/MJ3&K2FGR/GE:ZC"<9-
MKI[JUOW[=28.I) /(&3P>GUQCOV_I2>8F"V>!U.&X_2HXR,<?-D,-PS\WY]1
M@8! YXP2.:8TBKA1@,<]F*GE!@MRJMEU(5B&.=R@A6*B4K--)U.B3LGYV=VE
MW[=1<UDE/]W*5N5RTC%O[,[M:K9ZKY$PEC*[@3M]=K?R(S^E.#J>0?T/^%4X
MYXRK#JR_>&TC .2,@ %<C;G=Z@=2 98Y8Y$CD4Y5P"F.A4C*D9P>>O..N#SQ
M2YN5QA4C*-1V5G;E;M]E]5?9]@3;3J*=.=&-X2G!W_>Q;4DFI2C;F3TU?F]R
MS_G\J*!_4_SYHIE*]E?>VH4444#"BBB@ HHHH **** "BBB@ HHHH C>5$^\
MV.0/NL>3TQ@'/7M2>=%D*&R2,X 8GGIT!Y/8=3V%4;^X6T@O+N9F6"VADN'9
M 'D"0Q!Y!&C@KN*J<=02>1G!KX=/[?7PCCUHZ6VA?$!I4U%]-%P-)T!K7S$N
M%M3-O;Q"EYY1=D)'V?>-QVQ[5KHPV$Q&*G65&E*I"C251N.K6EVY-V7+'KU]
M3Q,VXBR7(:F'AG&8X?"/&/DPL9R49SJ.R4+-N[;DEHDS[R#J1D'CZ'^HKD?&
M?C3PSX$T'4_$_BS5HM*T/1XFNK^^D%P3;HL2%((4M899+FZN'9!!9@&>=IE6
M.-P4%;VG7#7=O!<@,(KB))E20*'195WA6",Z!U+8)1BI(.&(P3Y%\:OBM\'_
M (-^'[?Q?\:/$WA_PSH%KJ 33+W6H)[Z3^U3;O+&+&RMK2^O9+A8HI&VV=C=
MNF$D;RW9%;.A2K5:U*A3PU?&5JC2]A@TG5<GJXQ7+4?,K/[+[VT.RKCJ$<#4
MQD\5A\%2C#GCB,;IAW%I.,])TVX2BU)6FFT]S\KOCW^V9^VYX^DNH_V5?V8O
MB?IG@F%IEA\?^,? 5]-KVN1F*-4OO#GA^\.GQZ=:R$.UI-(MY)<6YBNB$>X,
M*_C)\3?VJ_VX]/\ $TMC\1_B;\7?!OB57>630M2@OO",\*VT298:+=:99-;V
MZPK$WGK"+>XW?:8IIUG65_ZRS^TS\ #\*IOC2/BGX73X:17#QS^*%EDEMHKZ
M)VC:P^PFW;6#J6Y9'33$LCJ'EJ62V6.,[?%?&/A3]E3_ (*(_"K4K'2=?T#X
M@Z5972VMAXHT2VGL-;\(ZVQDECO(8KRSL-3AD.[#0ZE;_P!EWPBE7:\T4[1_
MI_#O$V%R:G"AFW ="6 IXGZEC<56PV)680]G)0JRJUYM4%7;5Y+DC:37[E*T
M5^$<:\'YCQ"I8S(?$ZM'.ZT)9AA<AP^-PL:6*P]9NK2A@*,6Z\:,J<DJ$INL
MN2RE4;3D_P"<GX:?\%-?VPOAO/$9?B9<^,=.\V"4Z7XRTVUU\-:DK*\:7LSZ
M?=6/V@,72: W1".I"@?(/WI_8P_X*7_#7]IVXM/!'BBV/PY^*A+1P:!>7#W>
MA>*=@:0R>&=9D@B!N! 8C-I5^+2_6Z$R6B7]JD5S/_,1^TC\)_\ A2'QT^(O
MPGC74C!X/UU-.L;C5[2VL;S4+&XM+>ZL=2>&SGN;%5U*&87D0MKF2/RID8B(
MMY:^.Z/JVIZ!JFF:]H%_/I>MZ5>QZOI6L1221W6E7<441@N-+,1W1WD@15+2
M[8@"1(17ZQGG _#7$^3QQF3Y9#+W7H0Q&"=-1C6=&K352A]8M'EJSY)1]I:,
M%*7,X\MTS\/R#Q,XPX/S=X3,,=B<2L!F5;!9UA,UE.O5H1PM=T,0J/LY4>2<
M7":4I1G'1>ZUH?Z#$<L2QK@L%RV-R2#DL21\RY!!; 7MT &T@%?G_P#\$]?V
MJQ^U'\#++4M;C9/''@:X@\,>-4D?S6O'M[%KO2?$2*NXM)J<48ANXT>21M0L
M[V95%O);,2OY:S; 8[)<PQ.6UZ253"5946K2VA)QB[MJZE'EE%V5XRONF?W#
MD>:T>),KP6<Y5.-;!8_#4,32DTYS7MJ4*KA-P=E./-:2LFFGH?SH?M-_M2?M
M%^'?VC/V@_#^A?&?X@:9H>B?''XNZ5HVF:7K\MM;6NG6WC#6M)L+9;62$01P
M:?;6T0C1')=4#*JNQ0?L_P#\$NOVY;GXY>%?^%0_%374O/BEX0MA;:=K&H2*
M=0\9Z+&8I6FW+$JM>VL4T-N4.RXN8[>69(Y?LTSK_/)^UBP3]J/]I9FSA?CU
M\:)CA68^7#\0O$;R$*H+,57D(H+N>$5CQ7&^%/%/Q ^ GQ-L/$FBF;PM\0/
M.NY6._A4"'4O#][+(]O< ,T5Q!&WVZ$G=);ZA%>PO:-<P;7K^H<QX/RS/>&,
MNH4Z5+#9JL@R[%865!4X2K5I8##S4ZO-&4I.I)WGR.'-=Z;)?P[E7B/Q!PSQ
M?Q#FN*S#&8G)<)GZIUJ-24IT*%'%YC6A6HTTFE&%"'NX=2;<.6/.YZW_ +UH
M9T,8V$[6<I%E65MZGYE((!7;DCY@ <9!P17YT?\ !5'QSXR\ ?L?^,_$'@C7
M=0\.:\==\%6":II=RUI>10W_ (HTR&98YXR'3?$&R5/.,$@X!]^_92_:2\'_
M +4?PA\.?$OPW/#:7TJ0P>*?#\K%+[P]KVTQ7%C=Q,J8%RZ"ZLI(O,AG@N(Q
M'*\BNH^6O^"O3!OV*?&;#H?%OPYQP0>?%-CG(."#D8*L 0000#D5_/V0X*I@
M>,<MRS,*'^T4<=2H8BG5C>$JE*K*G4BTUJF^6::=FG&2>S7];\89M1S'PWSW
M.\GQDG3JY)C,RPF)IS7MH6JP]G:4?AY83<9QTDIIJZU1\B_\$9_B?\1_'_B/
MXWVGC3QGXC\6VNFZ7X?EL/[>UB[U,VS27VHP%X8YF<0>;;Q1N%8*V' (R&V_
MO@A$:6B D(!C.59?E8C&Y,IT X!SC@XPP'\ZO_!#=S'XF^/3%'F']C>%RJHR
MI-D7.HNMO!ATC;S3"Y+74D2*Y +JK(3]+^(/^"T?P.\-ZYK^AZG\)_B^]QX>
MUC4].N/]'\()F?2KJXMIYGC/B0SI$8;<W2AH1(T>R/;YP\NOI>-.'\=FG&&;
M8?)\LJ2H8&C&O7IT5%5(U(PJ*<Z:;C%4924Y13C*4HQ24FTV_D/#?BC*<E\/
M^&X<1YW-RS;,LPA1Q>)J*56=:C5YHTZM3E<7/1*I=17,WRVV7[2I*@C#,<#<
MPS@]F([#TQVIPFC) RW(R"4<*1[,5"GZ9S7!_#;QWH'Q.\ ^$_'_ (;F:70/
M&6A:9XCTEY!&9!8ZO"+JWCG\AYHDN8ED\JZ@$CO;SI)#,%D5E$WCGQ?I'@#P
MIXI\<:]));Z#X/T#5/$>LR00I/<_V9HMA/J%])!&TJ^;+':VLI2#'FS.HB@2
M21XT;\U]EB'6AA52E'$RER.E.,N>-3F5/D:]U\WM&H;+WNB/V6CBZ-7"O,'6
MI/!?5(XM5Z<O<=.5/VJFFVUR.#4DM[/?J=N74 DG@<'@]_;&3^%(94 +$D@
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/Q:]7=]6]V^X4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2533876d1_ex99-2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2533876d1_ex99-2img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !; 0@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBHO,//
MR].F6'/N, G]*=O4XP0<G Y[\9'3W%*ZO:^KO9:W=M[72O;=VO9:[:M-I*[<
M;:7?,M+Z*]F[7;LK]=-]!]%,W'., CL0W4XX&,<9Z=?SH#$_PX_/''X477K=
M<UUJK7MNKJ]^E[KM8$T[^3LTTT_N=G;L]GW'T5$9"#C;G'^]_P#$5(#D ],@
M''IG\!_(?2CF3=KZ^DOUBE^()I[.+[V:;7JEJA:***8PHHHH **** "BBB@
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M,../'?CWQ+X/XCG4S"OPAP_@<P6283+ZN5Y=CL94Q69Y/+%.&&PG]I*.!P&
MP6(PKQ>7TXYC&M5=9QJ?S;?LG?\ !3'XR?#_ ,<Z!X<^,/BC4/'WPTU*^L=.
MU6\\1L-0U_PO;2S6L$VMV6O!)-3O%MH9XKJ\M-4N=16]Q*EO<6!;S*_IJOI%
MFT.ZF1TD672YI%>,EHW62U9E>-CR48$%2>2I!/-?PGS1M'J;1N'247+"16!C
M<2-*HD2YC(RRJR.K0GRRI(7(\O#?V[_#VZFO_@QX&OKAB]Q>?#+PQ=3NQ+,\
MUQX6L9I6)/)+.[$D\DG)KD\1\GP&#Q.19G@L-#"O,,1AU7I48*.&4[4:UZ22
M23YI--*.JLV]-?8^@[XC\:<1Y+XJ<$<6YMF>=T>%,NCC,GQN<8K,<?BZ%/$4
M<ZRK,,'AL;FE2KCIY?/&8:.,IT,9-U</6J2AAG/!<DE_$GJKB/5+TMD 718X
M&?E\TG/Y8/XU^F[_ +??[1OB+X:_#CX)?LZ^'=<T&V\"^ /#'AG4]9\.:++X
MD\:ZY<:!HEC::C>64@TZ\CT739[BWD6R&GVMQ<K:['NM4M)R;=/S(U4%M4O.
M>MT5.1G*B5ACJ,<'&:_L!_8H\ ^$?"?[,7P;N/"^@:3HEQXF^'/A/Q%K]Q9V
M,4=SK&NZIH=I>7^J:G=QF*\O;N:XDD,;RW!%M$RV\ 2WC2,?:\99G@<HR_*\
M7CLKPV;3CB$\+A\9>6&C467TY3J58J_-^Z7+!6=I>\UHC^:OHM\#<9^(/&_B
M5D'"OB%C_#S+ZF6UI\58[)\.ZN=9ME4^+LRH8+*LLQ4)X;$9;4EF4W7Q&.PV
M.P=:-!>QYJL*TX4_Y@KO]I_]JSPEXFGEU3XS_%O2_$.FW:S7.EZSXW\5D6$Z
M-YDD=_H6HZD\0 7,T=E=:?-%]DDA &XS6\'[O?\ !.O]N76OVB[75/AG\3?)
MA^)WAC2%UFSUJ&%+-?%FAV\Z66HW%U8Q1_9[?5-.>;3Y+L612"]:]N)XK+3X
M;0Q-Y'_P6/\ A7X9'PX^'7Q6@T^"#Q?;^+&\%7FIV\0A?4-%U'0=<UB-;Y2S
M_:IM.N-$\O399C(UM!J%_%\ZS+M_,_\ X)L:K?:?^V5\'HK"8VR:I=>)].O5
M4,4FLI?!/BF>2W9-X!B>X6"=D)*^9;Q$#* CS<5A\JXMX-Q.<4,NPF78G#+%
MU*=.C3M4Y\ H+$Q5104?JM.,X.$&^:4IZ1ERMK[7AW-/$CZ.?TG\D\/,=QUG
MO&V0YSBLAP&9QS/,\PJT\QR;BV4H8+$T<MQN,QE' 9]@)4E_M"Q,U2IT*^%A
M7K4<3&1_7$I((#*"#)M4C^%&/RXQZ8(?/.3R<]7IN(7 (SNV@]@2>,GN!U/Y
M=JC59% 7S,E0N3L W8(;)&[@E"$..I4-QPHEW$+SC 7 ?T;D<  GT[]NO4C\
M%=E3YIR2BESN;=E&$>9Q;OMS)MZ7>FJN['^O^]3F5G_$C""LE:/[M\M[>[*4
M.=1>L7SW2NK_  9_P4_M-'NOV OVKDUM;=[1/A%XAO($N2JQG7+%;.]\.NA=
M6 N8]<MM--KS@W0A&QI#'C_.8!R <LS8#-E0#@C.6YP&/4KC@FO[3?\ @X._
M:<T_X>?LSZ%^SMH^H,_C'XY:]I]_KEG;[Y+BQ^''@W4K35KNYN$BC=X3K7BN
MTT+3M.$SVL%Y;V6N*;D"SDCE_D6^ 7P$^)_[3/Q3\+_"#X2^'+CQ-XM\77(6
M"*W>2+3]-TZUFACU37-=U$021Z5X?TB&0WNIZK*C1):O9_9$O+N_@M*_LOP"
MPTLEX S3.\SK1PF7YCF-7&4\3B)JE2PN%PF%A@%BE*;C_'BJU9*%YM0=US.*
M?\?^.=>.><:9;DN7TO;XW!Y?&CRX:U:M7Q%7%?78TJL:?-*G&G4:PJG6Y:>K
MM+E5S]ZO^#<;X$:CKWQJ^+_[1.H6<RZ!\/?!,?P]\/W4ZE+>Y\5>-+ZRU/4#
M:R'Y#+HN@:$\6I1[6=(?%&DSA@LI5ROZ7/V*_P!E#P?^QI^SSX)^!_@^2.^D
MT>VDU7Q?XC%L+6X\6^.-76&?Q#XBN$D>>:**:ZB2QT:UFFG?3?#]CI.E/-<F
MR%Q(5_-OB5Q+_KKQAFV<4:KA@Z=59=EW*I1C4P& 3H8:LHM)Q^L14J[C)1E'
MVB4XQE=+^B_#SAM<)\)Y7E=1..*=-XO&+E<Y+%8JU2I"4J:G%NE=4KIM6CHV
ME<_@A_X*&_\ )^7[6G_9Q/Q7_P#4UU>O[_OV.Q_QB1^S">[?L]_!T8ZYQ\._
M#@.>?[N%'3 %?P _\%#?^3\OVM/^SB?BO_ZFNKU_?_\ L<AC^R1^R^0V /V?
M/@\2,=1_PKSPYQG/ZX-?M'C?>7 /AHTIPM"C#GE"44FN$<E<DE))RYHV4913
M2W3/R/P8C*/&7'_-'F]Z51037O)\3YKRRYK\JY'[THM\S3MRO8_)/_@M_P#\
M$[?^&B?AA-^TK\*=$W_&WX/Z'</XGTS3+4RW_P 1?ASIHEU&>)+:'+:AXI\&
MC[9JOAU!%<7.HZ5+JVA+%=7#:';6O\>?P/\ C1X__9T^*_@WXP_##5YM \9>
M ]9M]4TFX@\RX@N( 9;>^TW5++<6O])U.T^V:3?V#G[-J.GW\RR3Q,QE;_4'
MD@64%6(VDY(V#DYW G.<X.2 > 3NQO 8?P\?\%L/^"=3_LO?%B3X^_"K0I(_
M@7\6];N);S3],M"EE\-/B%?&6]NM!A6*54L-$\1"._U?PZ"T=C$L&H:(EI F
MFPW5X_ SCVABJ#\/>)I4*^#Q5+$PRN>-FI*K0K1E#$Y'%U+P=3$4VI82[24W
M.G!IJ,2?&?@NO@\1'CG(85,/5I5</+,HX6-G2Q-&4:F&S?EIVG*%&K>.(C"+
MG*-I2BXW9^<?[>/[07AS]JC]J/X@_'SPSIM[H>G_ !(L? &IW&CZD1YNE:MI
MOPY\(>&?$>G+<(H6ZM=/\1Z-JMG9WYBM_M]M;QW0@@$NP?W9_P#!,;:/V OV
M47PP)^#OAK"D8*X6Z(# 9P>2" 3@]^E?YQQ"XV#;L90A";MCAPZ ?.JL85CE
M;RXPL1#GS"%8[1_HX_\ !,3<?V /V4FW=?@YX:;&,\!;G*Y)SAB?PQT).:];
MZ0>!I97P7P=EM"-2%#!YMC:6&]I"I:AAZ>4KV&%YYI.K+"PY%4E%R4I0UE*5
M[^7X%8NMF7%?%&88AIU<7EV$E4E&46L35>/DZF-5FTE7G[6*@[3@ZJ4HQY7;
M\;/^#CC]FEM8\&_"']JO0-.)U#PI>S_";QY<6T9\YM#UU[K7/ U_.RKB!=.U
MZ/7M&CN9%EW77BS3HPZ;EC?\V_\ @@K^T(/A%^VK9_#O5[T0^%OV@?#&H> Y
MXW?R[9/%6F*_B?P7=S[CL66>XMM6\.:9"%+37/B(1>9&6$3_ -C7[6?P*TG]
MI;]G'XO_  -UE(&7XB>"M6TG2;N7Y/[+\36ZQZEX3U?)RV-'\5V&CZBWEM&6
M2U5 ZEM]?YN_A_6O&/P'^+^CZ[:PW&A_$#X0?$&RU1+259;>[T?Q;X)\1P31
MV;J0#]ILM5TJ.'4+5PP%Q'*P;:QC,^$^-I<;^&7$' V-E[;%Y;@,7@,'3GS3
MG/+,=[3$Y9B54DN2+P.94)81<TU4C#$\^E*+G&_$W!3X1\1,EXRPM\/A\=CL
M%B\5-64:>9811PU3".,7SSCC,#6E6DX1E2<Z-I/VCBG^Y_\ P<2_'YO'?[3G
M@'X$:9>F;1O@CX*CO]9M;>3>G_";_$F*TUR_@FA"@3S0>%]-\&&$M*&MX[N]
M  W,K?MW_P $/?V<Q\"/V'?"'B?5=/2T\8_'?4[KXKZU-+'BX&A:A!!IW@6U
M\UL2-:'PG8VFNVT3)$MM=>([]3&Y+3S?R&^&+?QG_P %&?V]]/CU"U>TUO\
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M')^QK^TWI</BO59(?@K\7Y-.\%?$]))':QT;S[J0^&_'[1[)%7_A#=7U&?\
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M%^'U/A#-\_S6&8SQCSV52<Z,J;C]6<LTQF8)1E=J2Y<3&&G5-CJ\<^.?P5\
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M *VVT8W1E<YQY0]01R7/(.[DYP" ,8Y#:J>=QW;MV<?4XZY"DD,0I&Y@">@
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MB!V !(JWIGAK3=$@2TT:RTW2K.,,R6VGZ=%8PK*?XQ#8R6MOM _A,&__ *:
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
